Business Wire

Midea Group Awarded as 2022 Forbes China TOP 50 Sustainable Development Industrial Enterprises

Share

Earlier this year, Forbes released its "2022 Forbes China Top 50 Sustainable Development Industrial Enterprises" list. Midea Group was included on the list for its outstanding performance in green manufacturing, carbon neutrality, sustainable development and ESG construction.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230213005693/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Midea Group Awarded as 2022 Forbes China TOP 50 Sustainable Development Industrial Enterprises (Graphic: Business Wire)

The assessment focused on the specific indicators of five dimensions, i.e., "management system, technological innovation, comprehensive benefits, resource allocation, and demonstration & promotion". The selected companies this year are all industrial enterprises that have been established for at least 10 years, and have an annual revenue of more than RMB 100 billion, along with a year-on-year increase in R&D investment of about 50%. They also demonstrate key advantages over their global counterparts and possess state-of-the-art technologies that are among the best in the world.

Over the course of 25 years, Midea has honed and perfected its sustainable development management system, which integrates the concept of sustainable development into virtually every step of production and operation, as part of its efforts to fulfill its commitment to creating shared value with stakeholders.

Midea Shunde Industrial Park utilizes distributed PV systems, energy storage equipment, high-efficiency HVAC equipment (including MDV8 multi-connected units), LINVOL digital intelligent elevators, energy recovery modules, and automated production lines to realize both a green office and low-cost carbon production. Its efforts have led to LEED & WELL certifications. Relying on its iBUILDING digital platform, Midea Shunde Industrial Park's carbon management system and power grid system are fully integrated, and carbon neutrality has been achieved in the office area as well.

The Midea Chongqing Factory currently leverages over 15 green and energy-saving technologies, 8 digital scene applications, 3 green certifications and consultations, and also boasts access to over 10 information systems. It has significantly increased the proportion of clean energy and green electricity by installing roof PV panels, photovoltaic curtain walls, and solar street lights. Midea Chongqing Factory has also obtained the PAS2060 carbon neutral certificate, becoming one of Midea's first zero-carbon pilot plants.

Guided by the most advanced carbon consulting, Midea Jingzhou Factory has made a zero-carbon pathway that includes four stages: planning & design, construction, operation, and transformation. It has also adopted key zero-carbon solutions to obtain both its green and zero-carbon certifications. Through its energy optimization and management, operation and maintenance costs will be reduced by 30%, and the plant's power consumption will be diminished by 5-20%. These are its carbon reduction efforts as such.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lori Luo   luory17@midea.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye